Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Bundle
Founded in 1998, Tianjin Ringpu Bio-Technology Co., Ltd. (ticker 300119) has evolved from an early entrant in China's animal health industry to a market leader with some 20 branches and subsidiaries by 2025 and recognition as a National Leading Enterprise in Agricultural Industrialization; the company, publicly traded on the Shenzhen Stock Exchange, reported 3.07 billion CNY in revenue for 2024 (up 13.32% year-over-year), invested 168 million CNY in R&D (8.08% of revenue) and operates a vertically integrated model-backed by over 400 engineers and 16 leading experts, a 28,500㎡ laboratory and a 36,200㎡ experimental animal center-producing APIs, drug preparations, vaccines, antibiotics, antivirals and disinfectants while leveraging a significant insider stake (~48.04%) alongside institutional holders (~9.38% as of July 2025) and strategic moves such as the 2024 acquisition of a 56.31% stake in Tianjin Zhongrui Supply Chain Management to deepen its pet-health footprint, contributing to a market capitalization near 8.75 billion CNY by late 2025 and positioning Ringpu among the top three domestic and top 15 global players with analysts forecasting about a 10% CAGR through 2025.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Intro
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) is a China-based animal health company founded in 1998. It develops, manufactures and sells veterinary pharmaceuticals, biological products and pet-health related products. The company became the first A-share listed enterprise focused on veterinary medicines when it listed on the Shenzhen Stock Exchange in 2010 under ticker 300119. By late 2025 Ringpu had grown into a national player with expanded downstream service and supply capabilities.- Founded: 1998
- Stock listing: Shenzhen Stock Exchange, 2010 (Ticker: 300119)
- Branches & subsidiaries: 20 (by 2025)
- Market capitalization: ≈ 8.75 billion CNY (late 2025)
- Strategic acquisition: 56.31% stake in Tianjin Zhongrui Supply Chain Management Co., Ltd. (2024)
- Recognition: Designated a 'National Leading Enterprise in Agricultural Industrialization' by multiple national ministries
| Year | Event | Key Data |
|---|---|---|
| 1998 | Company establishment | Entry into animal health industry |
| 2010 | Shenzhen Stock Exchange listing | Ticker: 300119 (first A-share veterinary medicines company) |
| 2024 | Acquisition | 56.31% stake in Tianjin Zhongrui Supply Chain Management Co., Ltd. |
| 2025 | Organizational scale | 20 branches & subsidiaries |
| Late 2025 | Market value | Market cap ≈ 8.75 billion CNY |
- Product sales: revenues from veterinary drugs (pharmaceuticals and biologics) sold to livestock and companion animal markets.
- Distribution & supply chain: integration of downstream logistics and supply services-strengthened by the 56.31% acquisition of Tianjin Zhongrui to capture pet-health retail and supply margins.
- Service & technical support: revenue from on-farm technical services, vaccination programs and after-sales support to large agricultural customers.
- R&D-driven pipeline: investment in new vaccines and biologicals to maintain pricing power and product differentiation.
- National scale: 20 branches/subsidiaries provide manufacturing, regional distribution and localized technical service coverage across key livestock and pet markets.
- Regulatory and institutional recognition: 'National Leading Enterprise in Agricultural Industrialization' status supports access to government procurement, agricultural projects and industry partnerships.
- Vertical integration trend: acquisition activity (e.g., Tianjin Zhongrui) indicates a push into pet-health retail/supply chain control versus pure manufacturing.
| Holding | Stake | Notes |
|---|---|---|
| Tianjin Zhongrui Supply Chain Management Co., Ltd. | 56.31% | Acquired 2024 to expand pet-health supply chain capacity |
| Public float | Listed on Shenzhen (300119) | Market cap ≈ 8.75 billion CNY (late 2025) |
- Market capitalization: ≈ 8.75 billion CNY (late 2025)
- Branch/subsidiary network: 20 (2025)
- Ownership expansion: majority stake (56.31%) in supply-chain subsidiary (2024)
- Regulatory endorsements: national-level agricultural industrialization recognition
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ): History
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) is a Shenzhen-listed biotech company focused on animal health products, vaccines and related supply-chain services. The company has grown from regional vaccine manufacturing into an integrated pet and livestock health platform through organic expansion and targeted acquisitions.- Listed on the Shenzhen Stock Exchange under ticker 300119.
- Strategic expansion into pet health and supply-chain services via acquisitions and stake purchases.
- Significant internal ownership that supports long-term strategic initiatives.
| Metric | Value |
|---|---|
| Stock ticker / Exchange | 300119.SZ / Shenzhen Stock Exchange |
| Institutional ownership (July 2025) | 9.38% |
| Insider / executive & employee ownership | 48.04% |
| Major recent acquisition (2024) | 56.31% stake in Tianjin Zhongrui Supply Chain Management Co., Ltd. |
| Primary business lines | Animal vaccines, veterinary biologicals, pet health products, supply-chain services |
- Product sales: vaccines and biologics for livestock and companion animals sold to distributors, farms and veterinary clinics.
- Services and supply-chain: logistics, distribution and integrated supply services (strengthened by 2024 Zhongrui acquisition).
- R&D and licensing: development of new biologics and potential licensing collaborations.
- Channel monetization: proprietary distribution networks and partnerships that increase margin capture.
- Diverse shareholder base with both institutional and retail investors.
- High insider ownership (~48.04%) aligning management incentives with long-term value creation.
- Institutional investor presence modest at ~9.38% (July 2025), leaving strategic control balanced between public investors and insiders.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ): Ownership Structure
Tianjin Ringpu Bio-Technology Co.,Ltd. is a publicly listed veterinary-pharmaceutical company on the Shenzhen Stock Exchange (ticker: 300119.SZ, ChiNext/GEM board segment). As a listed entity, its equity is held by a mix of institutional investors, retail shareholders and company insiders, with a free public float that enables regular secondary-market trading.- Listing: Shenzhen Stock Exchange (300119.SZ, growth-enterprise market)
- Shareholder types: institutional investors, retail investors, management/board holdings
- Corporate governance: board of directors, supervisory board and professional management in compliance with listed-company rules
| Key Corporate / Financial Metrics (latest annual) | Value |
|---|---|
| Estimated Annual Revenue | ≈ 2,079,208,000 CNY |
| R&D Investment | 168,000,000 CNY |
| R&D as % of Revenue | 8.08% |
| National innovation platforms | 6 |
| Municipal innovation platforms | 7 |
| Industry recognition | National Leading Enterprise in Agricultural Industrialization |
| Primary business focus | Research, development and manufacture of veterinary medicines and animal-health products |
- Mission: To be a leading company in China's animal health industry, focusing on the development and production of veterinary medicines.
- Core values: Foresight, Innovation, Integrity, Sharing.
- Strategic emphasis: industry leadership through R&D, platform-building and innovation commercialization.
- Public listing provides capital access to fund R&D (168 million CNY invested; ~8.08% of revenue) and expansion of manufacturing and innovation platforms.
- Institutional and retail investors incentivize transparency, governance and performance aligned with industry leadership goals.
- Recognition (National Leading Enterprise) and platform network (6 national / 7 municipal) attract government, academic and industry collaboration partners.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ): Mission and Values
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) operates a vertically integrated veterinary biotech platform that controls R&D, production, quality control and sales. The firm's stated mission centers on improving animal health and food safety through innovation, rapid product development and scalable manufacturing while maintaining regulatory compliance and cost-efficient supply chains. Core values include scientific rigor, biosafety, customer orientation and platform-driven innovation.- Vertical integration: in-house R&D → pilot testing → manufacturing → distribution and after-sales.
- Quality & compliance: integrated QC checkpoints across R&D, production and batch release to meet national and international standards.
- Innovation focus: platform investments to shorten time-to-market and expand therapeutic coverage.
- Discovery & design: internal discovery teams and expert panels identify targets and formulates for anthelmintics, vaccines, antibiotics and antivirals.
- Preclinical & animal testing: supported by an on-site experimental animal center for safety and efficacy evaluation.
- Pilot & scale-up: laboratory and pilot-scale manufacturing enable process optimization prior to commercial production.
- Commercial manufacturing & distribution: finished-dose production and a distribution network to domestic and export channels.
- After-sales & technical service: field support, pharmacovigilance and vaccination guidance for livestock and companion animal customers.
- R&D personnel: over 400 engineers and scientists, plus 16 leading experts and senior technical staff.
- Laboratory footprint: 28,500 m² dedicated lab and pilot facilities.
- Experimental animal center: 36,200 m² for GLP-compliant animal studies and product validation.
- Innovation platforms: 5 national-level and 7 municipal-level research platforms to support translational projects and collaboration.
- Anthelmintics: formulations for swine, cattle, poultry and aquaculture.
- Pet vaccines: viral/bacterial vaccines for companion animals.
- Antibiotics: veterinary antibiotics across key classes for bacterial infections.
- Antivirals: veterinary antivirals for epidemic control.
- Disinfectants: farm and facility disinfectants for biosecurity.
- Direct sales of finished products to distributors, large farms, veterinary clinics and retailers.
- Contract manufacturing & OEM services leveraging pilot and commercial capacity.
- Licensing & technology transfer from in-house IP developed on national/muncipal platforms.
- R&D services and partnerships with agribusinesses, universities and government projects.
- Export sales to selected overseas markets-leveraging product lines with international registration where available.
| Aspect | Ringpu Capability / Metric |
|---|---|
| R&D staff | >400 engineers; 16 leading experts |
| Lab scale | 28,500 m² |
| Experimental animal center | 36,200 m² |
| Innovation platforms | 5 national, 7 municipal |
| Core product categories | Anthelmintics, pet vaccines, antibiotics, antivirals, disinfectants |
| Vertical integration benefit | Tighter QC, lower COGS potential, faster scale-up |
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ): How It Works
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) operates as an integrated animal-health pharmaceuticals and biologicals company, combining upstream active pharmaceutical ingredient (API) production with downstream finished formulations, vaccines and biological products. Its business model emphasizes end-to-end control, R&D-driven product development, and multi-channel distribution across livestock and companion animal markets. For more on the company's background and strategic context see: Tianjin Ringpu Bio-Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money- Core offerings: veterinary raw materials (APIs), drug preparations (formulations), functional feed additives, vaccines, biological products and disinfectants.
- Market coverage: food-animal (poultry, swine, ruminants) and companion animals (pets), with growing pet-health exposure after 2024 acquisition activity.
- Value chain integration: API synthesis → intermediate processing → finished formulations → distribution and after-sales support.
| Metric | 2024 | YoY Change | Notes |
|---|---|---|---|
| Total revenue (CNY) | 3.07 billion | +13.32% | Reported FY2024 |
| Major revenue streams | API & raw materials; finished drugs; vaccines; functional additives; disinfectants | - | Diversified product mix across animal health segments |
| Strategic acquisition | 56.31% stake in Tianjin Zhongrui Supply Chain (2024) | - | Expanded pet health & supply-chain capabilities |
| Integration benefits | Lower COGS; quality control; faster product cycles | - | Enhances gross margin potential |
- How revenue is generated:
- Direct sales of APIs and intermediates to pharmaceutical manufacturers and internal use for own formulations.
- Sales of finished drug preparations (oral, injectable) to veterinary distributors, large farms and farm cooperatives.
- Vaccine product sales and contract manufacturing for biologicals and immunogens.
- Functional additives and disinfectants sold to feed producers, farms and sanitation suppliers.
- Pet-health sales and distribution growth following the 2024 acquisition, adding retail and supply-chain revenue channels.
- Profitability levers:
- Vertical integration reduces procurement costs and improves margin control.
- Proprietary APIs and registered vaccine formulas protect pricing power.
- R&D-driven new products support premium pricing and market share gains.
- Scale advantages in production and distribution lower per-unit fixed costs as revenue grows.
- R&D and registration: sustained investment in veterinary R&D to renew product approvals, develop biologics and improve formulation efficacy.
- Manufacturing footprint: in-house API synthesis and formulation lines enable flexible production scheduling and quality traceability.
- Distribution and channels: combination of direct sales, third-party distributors, and the expanded pet-supply network via Tianjin Zhongrui.
- Market expansion: geographic expansion into higher-growth regional markets and increased penetration in the companion animal segment.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ): How It Makes Money
Tianjin Ringpu Bio-Technology generates revenue primarily through R&D-driven product sales, integrated supply-chain services for animal and pet health, and downstream distribution of veterinary pharmaceuticals and biologicals. The company's commercial model combines in-house manufacturing, technology licensing, and strategic acquisitions to capture value across the animal-health ecosystem.- Core product lines: veterinary vaccines, biological reagents, companion-animal therapeutics, and preventive products sold to farms, clinics and distributors.
- Service & distribution: supply-chain and logistics solutions for pet-health channels following the 56.31% stake acquisition in Tianjin Zhongrui Supply Chain Management Co., Ltd. in 2024.
- Innovation monetization: licensing of proprietary biologics and platform technologies developed across national and municipal innovation platforms.
| Metric | Value / Detail |
|---|---|
| Market position (domestic/global) | Top 3 in China; Top 15 globally (animal health) |
| Market capitalization (12‑Dec‑2025) | ≈ 8.75 billion CNY |
| Strategic acquisition | 56.31% stake in Tianjin Zhongrui Supply Chain Management Co., Ltd. (2024) |
| Innovation platforms | 6 national platforms; 7 municipal platforms |
| Analyst revenue outlook | Projected CAGR ≈ 10% through 2025 |
- Revenue drivers: scale in vaccine production, growth in companion-animal products, higher-margin biologics, and expanded logistics/distro from Tianjin Zhongrui.
- Margins & profitability: improved by proprietary biologics and platform licensing; efficiency gains from integrated supply-chain operations.
- Future growth levers: R&D commercialization from six national innovation platforms, pet-health expansion, and continued M&A to consolidate domestic distribution.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.